





|
|
Don't Give Up Hope!
By Janis Roszler, RD, CDE, LD/N
Well, it’s gone. The first inhaled insulin has left the marketplace.
When I first learned that Pfizer Inc, the largest drug maker in the world, had
dropped their support for Exubera, the first inhaled insulin, my heart sank. I
truly believed that this product was going to usher in a new era in diabetes
treatment. It wasn’t a perfect item, but I hoped that its presence on the market
would encourage other companies to research different forms of insulin. Just
imagine…insulin candies or Listerine-type insulin breath strips that dissolve
under your tongue. Wow. The sky was going to be the limit.
But, after spending close to $3 billion (gasp!) on Exubera, Pfizer called it
quits.
My buddy David Kliff, publisher of Diabetic Investor, brought up several
worrisome points when I called to discuss Pfizer’s decision. He said that the
failure could scare others away from bringing new forms of inhaled insulin to
the marketplace and that consumers might also become more wary of newer
products. After all, Exubera was a bust, so why should they trust their health
to another brand of inhaled insulin?
David believed that that Pfizer’s marketing strategy was flawed from the very
beginning. Pfizer knew that it had a good medication, but they didn’t pay
attention to the needs of insulin users or physicians. Doctors found it time
consuming to instruct patients on how to use the inhaler and convert their
injected insulin doses to an inhaled dosing scale. The inhaler, the size of a
half-liter bottle, was cumbersome and the cost of Exubera was very high at about
$600 a year more than injected insulin.
Now the ball is in our court. If we want new advances to come onto the scene, we
have to let everyone know that we are willing to keep an open mind and evaluate
each product on its own merit. To help accomplish this, try the following:
- Write letters of support to
individual manufacturers.
- Share your thoughts with your
health care team. Pharmaceutical representatives visit medical offices
regularly and can learn how you feel when they meet with the staff.
- Email a diabetes organization,
such as the American Diabetes Association at
diabetes.org or the
Diabetes Research Institute at
diabetesresearch.org, and let them know that you support ongoing
research to develop new insulin delivery systems.
- Participate in research studies
that test new forms of insulin. Visit
clinicaltrials.gov
to search for studies that are recruiting in your area.
Don’t let the failure of Exubera
discourage you. Keep an open mind and look to the future. With your voice, we
can support new research and develop new and improved treatments that will, one
day, lead us all to a cure.
|
 |
|